171 related articles for article (PubMed ID: 37887325)
1. SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer.
De Marco K; Lepore Signorile M; Di Nicola E; Sanese P; Fasano C; Forte G; Disciglio V; Pantaleo A; Varchi G; Del Rio A; Grossi V; Simone C
Cells; 2023 Oct; 12(20):. PubMed ID: 37887325
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Zou JN; Wang SZ; Yang JS; Luo XG; Xie JH; Xi T
Cancer Lett; 2009 Jul; 280(1):78-85. PubMed ID: 19321255
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3.
Parenti MD; Naldi M; Manoni E; Fabini E; Cederfelt D; Talibov VO; Gressani V; Guven U; Grossi V; Fasano C; Sanese P; De Marco K; Shtil AA; Kurkin AV; Altieri A; Danielson UH; Caretti G; Simone C; Varchi G; Bartolini M; Del Rio A
Eur J Med Chem; 2022 Dec; 243():114683. PubMed ID: 36116234
[TBL] [Abstract][Full Text] [Related]
4. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
Wang T; Wu H; Liu S; Lei Z; Qin Z; Wen L; Liu K; Wang X; Guo Y; Liu Q; Liu L; Wang J; Lin L; Mao C; Zhu X; Xiao H; Bian X; Chen D; Xu C; Wang B
Cancer Lett; 2018 Aug; 430():11-24. PubMed ID: 29746925
[TBL] [Abstract][Full Text] [Related]
5. Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-β1 in Gastric Cancer.
Liu H; Liu Y; Kong F; Xin W; Li X; Liang H; Jia Y
J Am Coll Surg; 2015 Aug; 221(2):579-90. PubMed ID: 26077602
[TBL] [Abstract][Full Text] [Related]
6. SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner.
Zeng Y; Ma G; Cai F; Wang P; Liang H; Zhang R; Deng J; Liu Y
Cell Death Dis; 2023 Jun; 14(6):386. PubMed ID: 37386026
[TBL] [Abstract][Full Text] [Related]
7. SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Liu Y; Luo X; Deng J; Pan Y; Zhang L; Liang H
Tumour Biol; 2015 Apr; 36(4):2685-94. PubMed ID: 25472580
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Liu Y; Liu H; Luo X; Deng J; Pan Y; Liang H
Tumour Biol; 2015 Jun; 36(6):4377-86. PubMed ID: 25627005
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Liu Y; Deng J; Luo X; Pan Y; Zhang L; Zhang R; Liang H
Med Oncol; 2015 Jan; 32(1):404. PubMed ID: 25471787
[TBL] [Abstract][Full Text] [Related]
11. Discovery of tetrahydrofuranyl spirooxindole-based SMYD3 inhibitors against gastric cancer via inducing lethal autophagy.
Zhu HP; Chai J; Qin R; Leng HJ; Wen X; Peng C; He G; Han B
Eur J Med Chem; 2023 Jan; 246():115009. PubMed ID: 36527933
[TBL] [Abstract][Full Text] [Related]
12. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Zhang H; Zheng Z; Zhang R; Yan Y; Peng Y; Ye H; Lin L; Xu J; Li W; Huang P
Cell Death Dis; 2021 Jul; 12(8):731. PubMed ID: 34301921
[TBL] [Abstract][Full Text] [Related]
13. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
Zhao L; Yasumoto K; Kawashima A; Nakagawa T; Takeuchi S; Yamada T; Matsumoto K; Yonekura K; Yoshie O; Yano S
Cancer Sci; 2013 Dec; 104(12):1640-6. PubMed ID: 24118504
[TBL] [Abstract][Full Text] [Related]
14. HGF-mediated crosstalk between cancer-associated fibroblasts and MET-unamplified gastric cancer cells activates coordinated tumorigenesis and metastasis.
Ding X; Ji J; Jiang J; Cai Q; Wang C; Shi M; Yu Y; Zhu Z; Zhang J
Cell Death Dis; 2018 Aug; 9(9):867. PubMed ID: 30158543
[TBL] [Abstract][Full Text] [Related]
15. SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation.
Wang P; Zhao L; Rui Y; Ding Y
Cancer Gene Ther; 2023 Apr; 30(4):575-581. PubMed ID: 36127410
[TBL] [Abstract][Full Text] [Related]
16. Identifying novel SMYD3 interactors on the trail of cancer hallmarks.
Fasano C; Lepore Signorile M; De Marco K; Forte G; Sanese P; Grossi V; Simone C
Comput Struct Biotechnol J; 2022; 20():1860-1875. PubMed ID: 35495117
[TBL] [Abstract][Full Text] [Related]
17. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
Ahn SY; Kim J; Kim MA; Choi J; Kim WH
Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
[TBL] [Abstract][Full Text] [Related]
18. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z
Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385
[TBL] [Abstract][Full Text] [Related]
19. Correlation between HGF/c-Met and Notch1 signaling pathways in human gastric cancer cells.
Huang KH; Sung IC; Fang WL; Chi CW; Yeh TS; Lee HC; Yin PH; Li AF; Wu CW; Shyr YM; Yang MH
Oncol Rep; 2018 Jul; 40(1):294-302. PubMed ID: 29781036
[TBL] [Abstract][Full Text] [Related]
20. Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Kim HJ; Kang SK; Kwon WS; Kim TS; Jeong I; Jeung HC; Kragh M; Horak ID; Chung HC; Rha SY
Int J Cancer; 2018 Jul; 143(1):151-159. PubMed ID: 29435981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
